ISAACS STEPHEN T 4

4 · ADURO BIOTECH, INC. · Filed Sep 6, 2018

Form 4

Period: 2018-09-05

DirectorPresident and CEO

Transactions

Sale
Common Stock
2018-09-06$7.92/sh−46,987$372,024→ 205,746 total
Sale
Common Stock
2018-09-05$7.90/sh−15,585$123,134→ 205,746 total
Exercise/Conversion
Stock Option (right to buy)
2018-09-05−15,585→ 810,894 total
Exercise: $1.00Exp: 2024-07-30→ Common Stock (15,585 underlying)
Exercise/Conversion
Stock Option (right to buy)
2018-09-06−46,987→ 763,907 total
Exercise: $1.00Exp: 2024-07-30→ Common Stock (46,987 underlying)
Exercise/Conversion
Common Stock
2018-09-05$1.00/sh+15,585$15,585→ 221,331 total
Exercise/Conversion
Common Stock
2018-09-06$1.00/sh+46,987$46,987→ 252,733 total

Holdings

Footnotes (5)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2017.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $7.925, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F3]The shares subject to the Option are fully vested and exercisable.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
[F5]The shares owned directly by the Isaacs-MacBride Family Trust UAD 03/09/01, for which the Reporting Person is a trustee.

Documents

1 file